Evidence map›Paper›PMID 32696187›Full record

Observational studyInternational urogynecology journal2021

Botulinum injections for myofascial pelvic pain.

Swati Jha, Philip Toozs-Hobson, Joanna C Roper, Sabitra Gurung, Amallia Brair, Fiona Bach

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in International urogynecology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05617118 (Evaluation of Efficacy and Safety of Oral Baclofen Taking in Comparison With Botulinum Toxin A Injections in Myofascial Pelvic Pain Syndrome. Prospective Multicenter Cohort Study.), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05617118 unknown statusnot on this mapstarted 2022, after this paper: background citation

Evaluation of Efficacy and Safety of Oral Baclofen Taking in Comparison With Botulinum Toxin A Injections in Myofascial Pelvic Pain Syndrome. Prospective Multicenter Cohort Study.

TypeobservationalSponsorSaint Petersburg State University, RussiaRan2022 to 2024Enrolled52ConditionsChronic Pain, Chronic Pelvic Pain Syndrome, Myofascial Pain Syndrome, Myofascial Trigger Point PainArmsBaclofen 10mg, Botulinum toxin type A
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Swati JhaDepartment of Urogynaecology, Sheffield Teaching Hospitals NHS Foundation Trust, Jessop Wing, Tree Root Walk, Sheffield, S10 2SF, UK.
Philip Toozs-HobsonDepartment of Urogynaecology, Birmingham Women's & Children's Hospital NHS Foundation Trust, Birmingham, B15 2TG, UK. p.toozs-hobson@nhs.net.
Joanna C RoperDepartment of Urogynaecology, Croydon University Hospital, 530 London Road, Croydon, CR7 7YE, UK.
Sabitra GurungDepartment of Urogynaecology, Birmingham Women's & Children's Hospital NHS Foundation Trust, Birmingham, B15 2TG, UK. sabitra00@yahoo.com.
Amallia BrairDepartment of Urogynaecology, Birmingham Women's & Children's Hospital NHS Foundation Trust, Birmingham, B15 2TG, UK.
Fiona BachDepartment of Obstetrics and Gynaecology, Christchurch Women's Hospital, Christchurch Central City, New Zealand.
Birmingham Women’s and Children’s NHS Foundation Trust · GBChristchurch Hospital · NZCroydon University Hospital · GBJessop Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introduction and hypothesisThe aim of this study was to assess the impact of botulinum toxin injection in women with myofascial pelvic pain (MFPP) syndrome of the pelvic floor who had failed conservative treatment.

methodsThis was a retrospective descriptive observational study of 48 consecutive patients receiving botulinum toxin to the pelvic floor for MFPP syndrome in a tertiary teaching hospital over an 8-year period. Trigger points were identified, and botulinum toxin was injected into the pelvic floor at the trigger points in doses ranging from 50 to 200 units. The patient-reported global impression of improvement scale was used to evaluate the success at follow-up, and adverse effects were recorded.

resultsForty-six women attended for follow-up at 3-6 months. Of these, 34 (74%) reported an improvement in their symptoms (slightly better, much better, very much better), 12 (26%) had no change, and no patients reported worsening of symptoms. One patient (2%) reported transient postoperative faecal incontinence, which resolved after 2 weeks. There appeared to be no difference in outcome between the doses.

conclusionsBotulinum toxin injection into the pelvic floor of women with MFPP appears to be beneficial in those who have failed conservative treatment. Prospective studies, including dose-finding studies, are now required.

Indexed as

Botulinum Toxins, Type AMyofascial Pain SyndromesNeuromuscular AgentsFemaleHumansPain MeasurementPelvic PainProspective StudiesRetrospective StudiesTreatment OutcomeBotulinum Toxins, Type ANeuromuscular AgentsBotoxBotulinum toxinMyofascial pain syndromePenetration disorderVaginismus

Identifiers

PMID32696187
OpenAlexW3044890195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.